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Abstract 
We have previously described a number of lipophilic conformationally constrained spiro carbocyclic 
2,6-diketopiperazine (2,6-DKP)-1-acetohydroxamic acids as potent anti-trypanosomal agents. In this 
report, we extend the SAR analysis in this class of compounds with respect to in vitro growth 
inhibition of Trypanosoma and Leishmania parasites. Introduction of bulky hydrophobic substituents 
at the vicinal position of the basic nitrogen atom in the spiro carbocyclic 2,6-DKP ring system can 
provide analogues which are potently active against bloodstream-form T. brucei and exhibit 
significant activities towards T. cruzi epimastogotes and L. infantum promastogotes and intracellular 
amastigotes. In particular, compounds possessing a benzyl or 4-chlorobenzyl substituent were found 
to be the most active growth inhibitors, with activities in the low nanomolar and low micromolar 
ranges for T. brucei and L. infantum, respectively. The benzyl substituted (S)-enantiomer was the 
most potent derivative against T. brucei (IC50=6.8 nM), T. cruzi (IC50=0.21 μΜ) and L. infantum 
promastigotes (IC50=2.67 μM) and intracellular amastigotes (IC50=2.60 μM). Moreover, the (R)-chiral 
benzyl substituted derivative and its racemic counterpart displayed significant activities against L. 
donovani. Importantly, the active compounds show high selectivity in comparison with two 
mammalian cell lines.    
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1 INTRODUCTION 
Trypanosomatid protozoan parasites of the genera Trypanosoma and Leshmania are the aetiological 
agents of serious diseases; human African trypanosomiasis (HAT or sleeping sickness), Chagas 
disease and the leishmaniases (cutaneous, mucocutaneous and visceral). These three parasitic 
diseases severely affect human health, representing a huge social and economic burden. As recently 
as the turn of the century, there were estimated to be 0.3 million infections with T. brucei annually, 
although the numbers have since fallen significantly.[1] In Latin America, 5 - 8 million people are 
currently infected with T. cruzi,[2] and globally there are an estimated 1 million new infections with 
different Leishmania species each year.[3] Since there are no human vaccines, prevention and 
treatment of these devastating diseases relies on public health measures and chemotherapy. 
Unfortunately, the current drugs have many limitations.  
 
 Pentavalent antimony, the most widely prescribed treatment for visceral leishmaniasis, since 
its introduction several decades ago, has shortcomings which include serious side effects, the 
requirement for a prolonged course of treatment, and the emergence of drug resistance.[4] Similarly, 
other visceral leishmaniasis drugs which have emerged over the past 10−15 years, also have 
drawbacks. With paromomycin, difficulties include administration (injectable, long treatment) and 
region-dependent efficacy. With miltefosine, the problems are high cost, long treatment and 
potential for teratogenicity. With the liposomal amphotericin B, high cost is also an issue, together 
with the need for hospitalization and potential teratogenicity.[5]  
 
For HAT, the first-line treatment for second-stage infections, since its introduction in 1949, has been 
the arsenic-based drug melarsoprol. However, it kills 5% those treated.[6] In addition, increased drug 
resistance and high therapeutic failure rates have been reported recently in several foci.[7] 
Eflornithine, an alternative treatment, now given in combination with nifurtimox, is better tolerated, 
but difficult to administer.[8]  Despite the urgency to develop new drugs for these neglected diseases, 
research and development has been limited by the lack of commercial interest.  
 
We have previously reported on a series of acetohydroxamic acid analogues (Figure 1, compounds 
1a-c, 1f, 1g, 2, 6a-c, 6f, 7a, 7b) which have potent anti-trypanosome activity.[9] These compounds 
were derived from conformationally constrained lipophilic spiro carbocyclic 2,6-diketopiperazine 
(2,6-DKP) scaffolds by introducing an acetohydroxamic acid moiety (CH2CONHOH) into their imidic 
nitrogen atom. The hydroxamic acid unit (CONHOH) is indispensable for trypanocidal activity in this 
class of compound.[9] Thus, we assumed that these primary hydroxamic acids act by inhibiting a vital 
parasite metalloenzyme via the metal ion binding action of the hydroxamate group in the catalytic 
site. It was also found that the potency of these acetohydroxamic acid – based trypanocidal agents 
was affected by: (a) the structure of the spiro carbocyclic ring and, (b) the presence of alkyl 
substituents on either the basic nitrogen atom (N-methylation), or at its vicinal position (C-
methylation or benzylation) in the spiro carbocyclic 2,6-DKP portion. Notably, attaching a benzyl 
group to the position adjacent to amine nitrogen (C-benzylation) significantly improved the potency 
against T. brucei and T. cruzi (Table 1, compounds 1f, 1g, 2, 6f) relative to the parent compounds (1a, 
6a). This finding revealed that the stereoelectronic features and lipophilicity of the substituent at the 
above position play an important role in the potency of this class of hydroxamates. Subsequently, we 
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have shown that the introduction of a methyl substituent into the nitrogen atom of the hydroxamic 
unit (CONHOH) results in inactive compounds (Table 1, 1a, 2 vs 4, 5).[10]  
 
The present work is an extension of our ongoing efforts to enrich the structure-activity relationships 
based on variation of the alkyl or benzyl substituent at the position adjacent to the amine nitrogen 
of the 2,6-DKP ring. Thus, we incorporated at this position an isobutyl (compounds 1d, 6d, 7d), a 2-
(methylthio)ethyl (compound 1e) or a 4-chlorobenzyl group (compound 3). The trypanocidal 
properties of the newly synthesized compounds were assessed against cultured bloodstream-form T. 
brucei. In addition, compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d were evaluated for their activity 
toward three different Leishmania sp., whilst their cytotoxicity against two established mammalian 
cell lines was investigated. 
 
2 METHODS AND MATERIALS  
2.1 Chemistry 
Melting points were determined using a Büchi capillary apparatus and are uncorrected. 1H and 13C 
NMR spectra were obtained on Bruker MSL 400 (400 MHz 1H, 100 MHz 13C), Bruker AVANCE III 600 
(600 MHz 1H, 150 MHz 13C), Varian 300 (75 MHz 13C), and Bruker AVANCE 200 (50 MHz 13C) 
spectrometers, using CDCl3 or DMSO-d6 as solvent. Chemical shifts are reported in δ(ppm) with 
tetramethylsilane or solvent (DMSO-d6) as internal standard. Splitting patterns are designated as s, 
singlet; d, doublet; dd, doublet of doublets; t, triplet; td, triplet of doublets; q, quartet; qd, quartet of 
doublets; m, multiplet; br, broad; v br, very broad; sym, symmetrical. The spectra were recorded at 
293 K (20 °C) unless otherwise specified. Carbon multiplicities were established by DEPT 
experiments. 2D NMR experiments (HMQC and COSY) were performed for the elucidation of the 
structures of the newly synthesized compounds. Low resolution mass spectra were recorded on 
either an API 2000 LC-MS/MS system, using positive electrospray ionization mode or Thermo 
Electron Corporation DSQ mass spectrometer in chemical ionization (CI) in positive ion mode with 
methane as CI reagent gas or in electron impact (EI). High resolution mass spectra (HRMS) were 
determined on a hybrid LTQ-Orbitrap Discovery mass spectrometer under electrospray ionization 
(ESI) in positive or negative ion mode. Optical rotations were measured on a Perkin Elmer 341 
polarimeter at the sodium D line (589). Analytical thin-layer chromatography (TLC) was conducted 
on precoated Merck silica gel 60 F254 plates (layer thickness 0.2 mm) with the spots visualized by 
iodine vapors and/or UV light. Column chromatography purification was carried out on silica gel 60 
(70-230 and 230-400 mesh ASTM). Elemental analyses (C, H, N) were performed by the Service 
Central de Microanalyse at CNRS (France) or Department of Microanalysis of NCSR “Democritos” 
(Greece), and were within ±0.4% of the calculated values. The purities of the tested compounds 
were determined by analytical HPLC and elemental analysis. The obtained results correspond to 
>95% purity. Analytical HPLC was performed on a Thermo Finnigan HPLC system (Thermo Finnigan, 
San Jose, USA) consisting of a SpectraSystem P4000 pump, a SpectraSystem  100 degasser, a 
SpectraSystem  AS3000 autosampler, and a SpectraSystem  UV2000 PDA detector, controlled by a 
SpectraSystem  controller. ChromQuest 4.1 software was used for the management of the data. For 
the HPLC-DAD, a Supelco Analytical Discovery HS C18 (250 mm x 4.6 mm, 5.0 μm) column was used 
and the injection volume was 10 μL. The mobile phase consisted of H2O and 1% acetic acid (solvent 
A) and acetonitrile (solvent B), and solvent gradient of A/B was 95/5 to 0/100. The analyses were 
performed at r.t. with a constant flow rate of 1 mL/min using a gradient elution of 0-50 min. The 
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commercial reagents were purchased from Alfa Aesar, Sigma-Aldrich and Merck, and were used 
without further purification except for the benzyl bromoacetate. This reagent was purified by 
distillation in vacuo prior to use. O-(4-Methoxybenzyl)hydroxylamine was synthesized according to 
the literature reported method.[11] Organic solvents used were in the highest purity, and when 
necessary, were dried by the standard methods. Yields refer to chromatographically pure materials. 
 
The synthesis of compounds 1a-c, 1f, 1g, 2, 4, 5, 6a-c, 6f, 7a, 7b, 9, 10, 13, 17, 18, 21, 25, 31, 32, 35, 
39, 45, 46, 49, 52, 58, 66, 67, 74, 75, 77, 78, 80, 81, 83, 84 has been previously described in our 
published protocols.[9,10,12] The experimental details, physical and chemical data of compounds 14, 
15, 22, 23, 26, 28, 29, 36, 37, 40, 42, 43, 50, 51, 53, 55, 56, 59, 62-64, 68, 69, 71, 72, 76, 79, 82, 85-88 
are given in the present work (Supporting information). The new compounds 1d, 1e, 3, 6d, 7d, 48, 
60, 61, 65, 70, 73 (main manuscript), 11, 12, 16, 19, 20, 24, 27, 30, 33, 34, 38, 41, 44, 47, 54, 57, 
(Supporting Information) were synthesized as a part of this study. 
 
2.1.1 (S)-N-Hydroxy-2-(2-methylpropyl)-3,5-dioxospiro[piperazine-2,2'-tricyclo[3.3.1.13,7] decane]-
4-acetamide 1d 
 
Carboxylic acid 47 (1.33 g, 3.82 mmol) was treated with 1,1'-carbonyldiimidazol (743 mg, 4.58 mmol) 
in dry THF (75mL) as described for the preparation of 58 from 45.[9] Then, O-benzyl hydroxylamine 
hydrochloride (731 mg, 4.58 mmol) and triethylamine (509 mg, 5.04 mmol) were added, and the 
mixture was stirred at 28°C for 25 h under argon. The reaction was worked up following the same 
procedure described in 58, and the resulting viscous oil was chromatographed on silica gel column 
with AcOEt-n-hexane 1:1, as eluent, to afford the corresponding O-benzyl hydroxamate 60 as a 
white foamy solid, which strongly binds the aforementioned solvents. Removal of the entrapped 
solvents upon drying at 62-64°C under vacuum (10-3 mmHg) in an Abderhalden apparatus gave 60 as 
a glass solid (1 g, 58%). This compound appears in the 1H and 13C NMR spectra as a mixture of Z/E 
conformers. 1H NMR (600 MHz, CDCl3, 273 K) δ 0.96 (t, 6H, J=3.6, 6.0 Hz, CH(CH3)CH3), 1.05-1.30 (br 
s, 1H, 1-H), 1.39-1.60 (complex m, 3H, 4'e, 9'e-H, CHHCH(CH3)2), 1.61-1.99 (complex m, 10H, 3', 5', 6', 
7', 8', 10'e-H, CHHCH(CH3)2), 2.05-2.20 (complex m, 2H, 1', 4'a-H), 2.42 (~t, 1H, J=12.0, 12.6 Hz, 9'a-
H), 2.87 (t, 1H, J=13.2, 13.8 Hz, 10'a-H), 3.65 (~br s, 1H, 6-H), 4.04-4.41 (q, AB, 1.2H, JAB=15.0 Hz, 
CH2CONHOCH2Ph), 4.49-4.69 (q, AB, 0.93H, JAB=16.8 Hz, CH2CONHOCH2Ph), 4.85, 4.89 (s+s, 2H, 
CONHOCH2Ph), 7.28-7.43 (complex m, 5H, aromatic H), 8.61 (s, 0.38H, CONHOCH2Ph), 9.03 (s, 0.33H, 
CONHOCH2Ph); 
13C NMR (150 MHz, CDCl3, 273 K) δ 21.2, 23.6 (CH(CH3)CH3), 24.5 (CH(CH3)2), 27.0, 
27.3 (5', 7'-C), 31.1 (1'-C), 31.7 (4'-C), 32.7 (8'-C), 33.1 (9'-C), 33.9 (10'-C), 34.9 (3'-C), 37.9 (6'-C), 40.3, 
40.4 (CH2CONHOCH2Ph), 41.7 (CH2CH(CH3)2), 51.6 (6-C), 60.7 (2, 2'-C), 78.2, 79.6 (CONHOCH2Ph), 
128.6, 128.7, 128.9, 129.2, 129.4 (2, 3, 4, 5, 6-aromatic C), 134.2, 135.2 (1-aromatic C), 165.6, 170.8 
(CONHOCH2Ph), 174.9, 175.9 (3, 5-C); ESI
+MS: m/z 454.5 [M+H]+. 
 
Compound 60 (856 mg, 1.89 mmol) was subjected to catalytic hydrogenation (H2/Pd-C, 103 mg) in 
abs EtOH (90 mL) following the procedure previously described.[9] The hydrogenation product was 
chromatographed on silica gel column using AcOEt-n-hexane 1:1, as eluent, to afford the titled 
compound 1d as a white foamy solid, which strongly binds the eluting solvents. Removal of the 
entrapped solvents upon drying at 55°C under vacuum (10-3 mmHg) in an Abderhalden apparatus 
gave 1d as an off-white semifoamy solid (658 mg, 96%): 1H NMR (400 MHz, DMSO-d6) δ 0.91 (d, 6H, 
J=6.0 Hz, CH(CH3)CH3), 1.37 (d, 1H, J=11.6 Hz, 9'e-H), 1.41-1.51 (m, 2H, 4'e-H, CHHCH(CH3)2), 1.53-
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1.98 (complex m, 10H, 3', 5', 6', 7', 8', 10'e-H, CHHCH(CH3)2), 2.07 (s, 1H, 1'-H), 2.14 (d, 1H, J=12.0 Hz, 
4'a-H), 2.46 (d, 1H, J=11.2 Hz, 9'a-H), 2.69 (d, 1H, J=11.6 Hz, 1-H), 2.83 (d, 1H, J=10.8 Hz, 10'a-H), 
3.42-3.54 (~td, 1H, J=2.6, 11.1 Hz, 6-H), 4.05-4.20 (q, AB, 1.4H, JAB=15.6 Hz, CH2CONHOH, E-isomer), 
4.33-4.50 (q, AB, 0.4H, JAB=16.8 Hz, CH2CONHOH, Z-isomer), 8.82 (s, 0.57H, CONHOH, E-isomer), 9.24 
(s, 0.14H, CONHOH, Z-isomer), 10.10 (s, 0.15H, CONHOH, Z-isomer), 10.49 (s, 0.53H, CONHOH, E-
isomer); 13C NMR (75 MHz, DMSO-d6) δ 21.2, 23.5 (CH(CH3)CH3), 24.1 (CH(CH3)2), 26.7, 27.0 (5', 7'-C), 
30.3, 30.5 (1'-C, Z/E-isomers), 31.3 (4'-C), 32.2 (8'-C), 32.9 (9'-C), 33.4 (10'-C), 33.9, 34.0 (3'-C, Z/E-
isomers), 37.8 (6'-C), 39.6 (CH2CONHOH), 40.8, 40.9 (CH2CH(CH3)2, Z/E-isomers), 51.1 (6-C), 59.7, 
59.8 (2, 2'-C, Z/E-isomers), 164.2 (CONHOH, E-isomer), 169.6 (CONHOH, Z-isomer), 174.7, 174.8, 
175.0, 175.1 (3, 5-C, Z/E-isomers);       
   -29.5 (c, 0.2, CHCl3); HRMS (ESI): [M-H]
- calc for C19H29N3O4, 
362.2080, found, 362.2067. The hydrochloride salt (1d·HCl) was prepared by treating an ether 
solution of 1d with ethereal HCl under ice cooling. The white precipitate was collected by filtration, 
triturated with ether and dried in vacuo. Mp 200-203°C (dec). Anal. Calcd for C19H30ClN3O4: C, 57.06; 
H, 7.56; N, 10.51; Found: C, 56.72; H, 7.41; N, 10.82. 
 
2.1.2 (S)-N-Hydroxy-6-[(2-methylthio)ethyl]-3,5-dioxospiro[piperazine-2,2'-tricyclo 
[3.3.1.13,7]decane]-4-acetamide 1e 
 
A mixture of benzyl ester 34 (850 mg, 1.86 mmol) and 10% Pd on charcoal (1275 mg) in EtOH-AcOEt 
3:2 (70 mL) was hydrogenated as described for the preparation of 45 from 31[12] to give a white 
foamy solid (646 mg). The 1H NMR spectrum of the product material showed a mixture of the 
desired carboxylic acid 48 (purity ca. 91%, yield 86%) and some unchanged 34. The carboxylic acid 48 
was regarded as sufficiently pure to be used in the next reaction without further purification [48: 1H 
NMR (400 MHz, CDCl3) δ 1.48-1.59 (q, 2H, J=12.4 Hz, 4'e, 9'e-H), 1.61-1.93 (complex m, 9H, CHHCH2S, 
3', 5', 6', 7', 8', 10'e-H), 2.11 (s, 4H, 1'-H, SCH3), 2.18 (d, 1H, J=12.0 Hz, 9'a-H), 2.32-2.50 (m, 2H, 
CHHCH2S, 4'a-H), 2.63-2.80 (m, 2H, CH2S), 2.89 (d, 2H, J=12.0 Hz, 10'a-H), 3.86 (dd, 1H, J=3.4, 9.0 Hz, 
6-H), 4.30-4.62 (q, AB, 2H, JAB=17.6 Hz, CH2CO2H), 5.46-6.65 (v br s, 2H, 1-H, CO2H)]. This material 
(646 mg) was treated with 1,1'-carbonyldiimidazol (311 mg, 1.92 mmol) in dry THF (32 mL) as 
described earlier for the preparation of 58 from 45.[9] Then, O-benzylhydroxylamine hydrochloride 
(306 mg, 1.92 mmol) and triethylamine (214 mg, 2.11 mmol) were added, and the mixture was 
stirred at 28°C for 25 h under argon. The reaction was worked-up in exactly the same way described 
in 58, and the resulting viscous oil residue was chromatographed over flash silica eluting first with 
Et2O-n-hexane 1:1 and then AcOEt to afford the corresponding O-benzyl hydroxamate 61 as a 
colourless viscous oil, which binds the elution solvents. Removal of the entrapped solvents upon 
drying at 55°C under vacuum (10-3 mmHg) gave 61 as a glass solid (542 mg, 62% from 34). This 
compound appears in the 1H and 13C NMR spectra as a mixture of Z/E conformers. 1H NMR (600 
MHz, CDCl3, 283 K) δ 1.38-1.47 (br s, 1H, 1-H), 1.51 (d, 1H, J=12.4 Hz, 4'e), 1.56 (d, 1H, J=11.6 Hz, 9'e-
H), 1.64-1.91 (complex m, 9H, CHHCH2S, 3', 5', 6', 7', 8', 10'e-H), 2.11 (s, 3H, SCH3), 2.17 (~br s, 2H, 1', 
9'a-H), 2.34-2.50 (m, 2H, CHHCH2S, 4'a-H), 2.65-2.78 (m, 2H, CH2S), 2.83-2.95 (br s, 1H, 10'a-H), 3.78-
3.93 (br s, 1H, 6-H), 4.07-4.42 (q, AB, 1H, JAB=15.1 Hz, CH2CONHOCH2Ph), 4.54-4.73 (q, AB, 1H, 
JAB=16.8 Hz, CH2CONHOCH2Ph), 4.87, 4.91 (s+s, 2H, CONHOCH2Ph), 7.34-7.41 (m, 5H, aromatic H), 
8.19 (s, 0.44H, CONHOCH2Ph), 8.61 (s, 0.42H, CONHOCH2Ph);
 13C NMR (150 MHz, CDCl3, 283 K) δ 15.1 
(SCH3), 26.9, 27.2 (5', 7'-C), 30.4 (CH2S), 30.8, 31.0 (1'-C), 31.1 (CH2CH2S), 31.4 (9'-C), 32.5 (8'-C), 33.1 
(4'-C), 33.8 (10'-C), 35.0 (3'-C), 37.9 (6'-C), 40.2 (CH2CONHOCH2Ph), 51.7 (6-C), 60.9 (2,2'-C), 78.1, 
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79.5 (CONHOCH2Ph), 128.5, 128.8, 129.1, 129.2 (2, 3, 4, 5, 6-aromatic C), 134.1, 135.1 (1-aromatic C), 
165.5, 170.7 (CONHOCH2Ph), 174.7, 174.8 (3, 5-C); ESI
+MS: m/z 472.2 [M+H]+. 
 
Compound 61 (360 mg, 0.76 mmol) was subjected to catalytic hydrogenation (10% Pd-C, 550 mg) in 
EtOH-AcOEt 3:2 (35 mL) following the procedure previously described.[9] The hydrogenation material 
was chromatographed over flash silica eluting first with AcOEt-n-hexane 1:1 and then AcOEt to 
afford successively the unchanged compound 61 and title compound 1e as a white foamy solid, 
which strongly binds the elution solvents. Removal of the entrapped solvent upon drying at 62-64 °C 
under vacuum (10-3 mm Hg) in an Abderhalden apparatus gave 1e as an off-white solid (72 mg, 25%): 
mp 75-78 °C; 1H NMR (400 MHz, DMSO-d6) δ 1.39 (d, 1H, J=11.7 Hz, 4’e-H), 1.46 (d, 1H, J=11.7 Hz, 
9’e-H), 1.54-1.92 (complex m, 9H, 3’, 5’, 6’, 7’, 8’, 10’e-H, CHHCH2S), 2.05 (s, 3H, SCH3), 2.07 (s, 1H, 
1’-H), 2.12-2.29 (m, 2H, 9’a-H, CHHCH2S), 2.45 (d, 1H, J=10.8 Hz, 4’a-H), 2.67 (~t, 2H, J=7.3, 7.8 Hz, 
CH2S), 2.82 (~d, 2H, J=11.4 Hz, 1, 10’a-H), 3.60-3.75 (sym quintet, 1H, 6-H), 4.07-4.19 (q, AB, 1.36 H, 
JAB=15.6 Hz, CH2CONHOH, E-isomer), 4.21-4.31 (m, 0.38 H, CH2CONHOH, E-isomer), 4.36-4.53 (q, AB, 
0.35 H, J=16.8 Hz, CH2CONHOH, Z-isomer), 8.84 (s, 0.7 H, CONHOH, E-isomer), 9.26 (s, 0.2 H, 
CONHOH, Z-isomer), 10.12 (s, 0.2 H, CONHOH, Z-isomer), 10.52 (s, 0.7 H, CONHOH, E-isomer); 13C 
NMR (100 MHz, DMSO-d6) δ 14.4 (SCH3), 26.6, 26.9 (5’, 7’-C), 29.9 (CH2S), 30.1, 30.2 (1’-C), 30.8, 30.9 
(CH2CH2S), 31.1 (9’-C), 32.2 (8’-C), 32.8 (4’-C), 33.4 (10’-C), 34.0, 34.1 (3’-C), 37.8 (6’-C), 39.5, 39.9 
(CH2CONHOH), 51.3, 51.4 (6-C), 59.9 (2, 2’-C), 164.1 (CONHOH, E-isomer), 169.6 (CONHOH, Z-
isomer), 174.4, 174.6 (3, 5-C); HRMS (APCI+): [M+H]+ calcd for C18H27N3O4S 382,1756, found 
382,1791. The hydrochloride salt (1e∙HCl) was prepared as described for 1d∙HCl. Mp 139-143 oC 
(dec);       
   -22 (C, 0.1, DMSO). Anal Calcd for C18H28ClN3O4S: C, 51.73; H, 6.75; N, 10.05. Found: C, 
52.10; H, 6.98; N, 10.12. 
 
2.1.3 (RS)-6-[(4-Chlorophenyl)methyl]-N-hydroxy-2,6-dioxospiro[piperazine-2,2’-tricyclo 
[3.3.1.13,7]decane]-4-acetamide 3 
A mixture of 4-methoxybenzyl ester 38 (1.0 g, 1.86 mmol) and TFA (3 mL) in CH2Cl2 (20 mL) was 
stirred for 90 min. The solution was evaporated to dryness under reduced pressure, and the residue 
was dissolved in dry THF (36 mL). Triethylamine (304 mg, 3 mmol) and 1,1’-carbonyldiimidazol (364 
mg, 2.24 mmol) were added, and the mixture was stirred at 28 °C for 1h under argon. After this time, 
O-(4-methoxybenzyl)hydroxylamine (344 mg, 2.24 mmol) was added, and the mixture was stirred 24 
h at 28 °C and 1 h at 55 °C under argon. The reaction was then worked up in the same way described 
for the preparation of 58 from 45[9]. The resulting thick oil was chromatographed on silica gel column 
with AcOEt-n-hexane 1:2, as eluent, to afford the corresponding O-benzyl hydroxamate 65 as a 
white foamy solid, which strongly binds the elution solvents. Removal of the entrapped solvents as 
in 60 gave 65 as a glass solid (715 mg, 70%). This compound appears in the 1H and 13C NMR spectra 
as a mixture of E/Z conformers. 1H NMR (600 MHz, CDCl3, 273K) δ 1.39-1.50 (m, 2H, 4’e, 9’e-H), 1.55-
1.88 (complex m, 10H, 1, 3’, 4’a, 5’, 6’, ‘7, 8’, 10’e-H), 1.99-2.17 (m, 2H, 1’, 9’a-H), 2.81-3.0 (complex 
m, 2H, 10’a-H, CHHC6H4Cl-4), 3.35 (~d, 1H, J=13.8 Hz, CHHC6H4Cl-4), 3.75-3.88 (m, 1H, 6-H), 3.78, 
3.81 (s + s, 3H, OCH3), 4.10-4.40 (q, AB, 1H, JAB=15.3 Hz, CH2CONHOCH2C6H4OCH3-4), 4.47-4.68 (q, AB, 
1H, JAB=16.8 Hz, CH2CONHOCH2C6H4OCH3-4), 4.80, 4.83 (s + s, 2H, CONHOCH2C6H4OCH3-4), 6.84-6.95 
(dd, 2H, J=8.4, 20.4 Hz, aromatic H), 7.14-7.36 (complex m, 6H, aromatic H), 8.53 (s, 0.4 H, 
CONHOCH2C6H4OCH3-4), 8.96 (s, 0.4 H, CONHOCH2C6H4OCH3); 
13C NMR (150 MHz, CDCl3, 273 K) δ 
26.9 (5’, 7’-C), 30.6 (1’-C), 31.3, 31.4 (4’-C), 32.5 (9’-C), 33.2 (8’-C), 33.9 (10’-C), 34.8 (3’-C), 37.3 (6’-
C), 37.9 (CH2C6H4Cl-4), 40.2, 40.3 (CH2CONHOCH2C6H4OCH3-4), 54.1, 54.2 (6-C), 55.3, 55.4 (OCH3), 
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60.9 (2, 2’-C), 77.8, 79.3 (CONHOCH2C6H4OCH3-4), 113.8, 114.1, 126.2, 127.2, 128.8, 130.6, 130.7, 
131.2, 132.8, 135.5, 159.9, 160.2 (aromatic C), 165.4, 170.6 (CONHOCH2C6H4OCH3-4), 173.7, 174.4 (3, 
5-C); CI+ MS: m/z 552.2 ([M+H]+, 1.5), 426. 2 ([M – CH2C6H4Cl-4]
+, 8), 137.0 (30), 121.0 (100). 
 
A mixture of compound 65 (451 mg, 0.82 mmol) and TFA (6 mL) in CH2Cl2 (23 mL) was stirred for 10 
min. The solution was then treated dropwise with Et3SiH (600 μL) via syringe, and the stirring was 
continued for 45 min at room temperature. In this time window, the colour changed from ruby to 
pale yellow. The reaction mixture was evaporated to dryness under reduced pressure, and the 
residual material was quenched with water (15 mL) and ether (50 mL) under vigorous stirring. To this 
stirred two phase mixture was added solid Na2CO3 to pH=8-9. The organic layer was separated and 
the water phase was extracted with ether (3 x 40 mL). The combined organics were washed with 
brine (50 mL), dried (Na2SO4) and evaporated to dryness. The thick oily residue was 
chromatographed on silica gel column with AcOEt-n-hexane 2:1, as eluent, to afford the title 
compound 3 as a white foamy solid, which binds the elution solvents. Removal of the entrapped 
solvents as in 1d gave 3 as an off-white semifoamy solid (313 mg, 89%): 1H NMR (400 MHz, DMSO-
d6) δ 1.30 (d, 2H, J=11.6 Hz, 4’e, 9’e-H), 1.48-1.73 (complex m, 5H, 4’a, 7’, 8’, 10’e-H), 1.76 (s, 1H, 5’-
H), 1.82 (s, 1H, 3’-H), 2.04 (s, 1H, 1’-H), 2.18 (d, 1H, J=12.0 Hz, 9’a-H), 2.69-2.92 (complex m, 3 H, 
CHHC6H4Cl-4, 1, 10’a-H), 3.30 (dd, 1H, J=3.2, 14.0 Hz, CHHC6H4Cl-4), 3.72 (td, 1H, J=3.2, 10.9 Hz, 6-H), 
4.16 (s, 1.4 H, CH2CONHOH), E-isomer), 4.38-4.53 (q, AB, 0.43H, J=16.8 Hz, CH2CONHOH, Z-isomer, 
7.29-7.40 (m, 4H, aromatic H), 8.87 (s, 0.72 H, CONHOH, E-isomer), 9.28 (s, 0.2 H, CONHOH, Z-
isomer), 10.16 (s, 0.2 H, CONHOH, Z-isomer),  10.55 (s, 0.7 H, CONHOH, E-isomer); 13C NMR (50 MHz, 
DMSO-d6) δ 26.5 (5’-C), 26.7 (7’-C), 29.9 (1’-C), 30.9 (4’-C), 32.0 (9’-C), 32.8 (8’-C), 33.3 (10’-C), 34.1 
(3’-C), 36.5 (CH2C6H4Cl-4), 37.7 (6’-C), 39.5 (CH2CONHOH), 54.1 (6-C), 60.0 (2, 2’-C), 127.9, 131.0 (2, 3, 
5, 6-aromatic C), 130.8 (4-aromatic C), 137.8 (1-aromatic C), 164.1 (CONHOH, E-isomer), 169.5 
(CONHOH, Z-isomer), 173.5., 174.5 (3,5-C); HRMS (ESI): [M + H]+, [M + Na]+ calcd for C22H26ClN3O4 
432.1690, 454.1510, found 432.1689, 454.1506. The hydrochloride salt was prepared as described 
for 1d∙HCl. Mp 179-182 °C (dec). Anal. Calcd for C22H27Cl2N3O4: C, 56.41; H, 5.81; N, 8.97; Found: C, 
56.06; H, 6.12; N, 8.65. 
 
2.1.4 (S)-N-Hydroxy-2-(2-methylpropyl)-3,5-dioxo-1.4-diazaspiro[5.7]tridecane-4-aceta-mide 6d 
Carboxylic acid 54 (1.13 g, 3.5 mmol) was treated with 1, 1’-carbonyldiimidazol (681 mg, 4.2 mmol) 
in dry THF-DMF 6:1 (70 mL) as described for the preparation of 58 from 45.[9] Then O-
benzylhydroxylamine hydrochloride (670 mg, 4.2 mmol) and triethylamine (468 mg, 4.62 mmol) 
were added, and the mixture was stirred at 28 °C for 25 h under argon. The reaction was worked up 
in exactly the same way described in 58, and the resulting viscous oil was chromatographed on silica 
gel column with AcOEt-n-hexane 2:3, as eluent, to afford the corresponding O-benzyl hydroxamate 
70 as a white foamy solid, which strongly binds the aforementioned solvents. Removal of the 
entrapped solvents as in 60 gave 70 as a white solid (1.07 g, 71.5%): mp 115-118 °C. This compound 
appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers. 1H NMR (400 MHz, CDCl3) δ 
0.95 (t, 6H, J=12.6 Hz, CH(CH3)CH3), 1.10-1.27 (br s, 1H, 1-H), 1.31-2.08 (complex m, 16 H, 7, 8, 9, 10, 
11, 12, 13-H, CH2CH(CH3)2), 2.17-2.35 (m, 1H, 13-H), 3.62 (d, 1H, J=22.0 Hz, 2-H), 4.12-4.40 (br s, 1H, 
CH2CONHOCH2Ph), 4.45-4.75 (br s, 1H, CH2CONHOCH2Ph), 4.88 (s, 2H, CONHOCH2Ph), 7.37 (s, 5H, 
aromatic H), 8.12-8.45 (br s, 0.5H, CONHOCH2Ph), 8.57-8.88 (br s, CONHOCH2Ph); 
13C NMR (50 MHz, 
CDCl3) δ 20.8 (9-C), 21.2 (CH(CH3)CH3), 21.4 (11-C), 23.5 (CH(CH3)CH3), 24.5 (10-C, CH(CH3)2), 27.4 (8-
C), 28.5 (7-C), 28.7 (12-C), 34.5 (13-C), 39.7 (CH2CONHOCH2Ph), 40.5 (CH2CH(CH3)2), 51.8 (2-C), 60.4 
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(6-C), 78.4, 79.5 (CONHOCH2Ph), 128.7, 129.3 (2, 3, 4, 5, 6-aromatic C), 135.0 (1-aromatic C), 165.6, 
170.7 (CONHOCH2Ph), 174.3, 177.2 (3, 5-C); CI
+ MS: m/z 430.2 ([M+H]+, 34), 429.3 ([M]+, 13), 373.2 
([M+H-CH2CH(CH3)2]
+, 18), 322.1 ([M-OCH2Ph]
+, 18), 307.2 ([M-NHOCH2Ph]
+, 22), 306.1 (49), 279.2 
([M-CONHOCH2Ph]
+, 100), 91.0 (90).   
 
Compound 70 (1.19 g, 2.8 mmol) was subjected to catalytic hydrogenation (10% Pd-C, 143 mg), in 
abs EtOH (126 mL) following the procedure previously described.[9] The hydrogenation material was 
chromatographed on silica gel column eluting first with AcOEt-n-hexane 1:1 and then AcOEt to 
afford the title compound 6d as a white foamy solid, which strongly binds the eluting solvent. 
Removal of the entrapped solvent as in 1e gave 6d as an off-white solid (850 mg, 90.5%): mp 129-
132°C; 1H NMR (400 MHz, DMSO-d6) δ 0.84 (d, 3H, J=6.4 Hz, CH(CH3)CH3), 0.88 (d, 3H, J=6.4 Hz, 
CH(CH3)CH3), 1.30-1.96 (complex m, 16H, 7, 8, 9, 10, 11, 12, 13-H, CH2CH(CH3)2), 1.97-2.10 (q, 1H, 
J=9.2 Hz, 13-H), 2.42-2.48 (m, 1H, 1-H), 3.36-3.53 (m, 1H, 2-H), 4.0-4.13 (q, AB, 1.5H, JAB=15.6 Hz, 
CH2CONHOH, E-isomer), 4.30-4.42 (q, AB, 0.4H, JAB=16.8 Hz, CH2CONHOH, Z-isomer), 8.79 (s, 0.8H, 
CONHOH, E-isomer), 9.21 (s, 0.2H, CONHOH, Z-isomer), 10.08 (s, 0.2H, CONHOH, Z-isomer), 10.43 (s, 
0.7H, CONHOH, E-isomer); 13C NMR (75 MHz, DMSO-d6) δ 20.4 (9-C), 21.0 (11-C), 21.1 23.5 
(CH(CH3)CH3), 24.0 (CH(CH3)2), 24.2 (10-C), 27.0 (8-C), 27.7, 27.8 (7-C), 28.3 (12-C), 33.4 (13-C), 39.2, 
39.3 (CH2CONHOH), 39.6 (CH2CH(CH3)2), 51.1 (2-C), 59.5 (6-C), 164.0 (CONHOH, E-isomer), 169.5 
(CONHOH, Z-isomer), 174.1, 176.9 (3, 5-C);       
   -11 (c, 0.2, CHCl3); HRMS (ESI): [M-H]
- calcd for 
C17H29N3O4, 338.2080, found, 338.2069. The hydrochloride salt (6d·HCl) was prepared as described 
for 1d·HCl. Mp 212-214°C (dec). Anal. Calcd for C17H30ClN3O4: C, 54.32; H, 8.05; N, 11.18; Found: C, 
53.98; H, 7.88; N, 10.89. 
 
2.1.5 (S)-N-Hydroxy-2-(2-methylpropyl)-3,5-dioxospiro-1,4-diazaspiro[5.6]dodecane-4-acetamide 
7d 
Carboxylic acid 57 (1.52 g, 4.9 mmol) was treated with 1,1'-carbonyldiimidazol (957 mg, 5.9 mmol) in 
dry THF-DMF 6:1 (100 mL) as described for the preparation of 58 from 45.[9] Then, O-
benzylhydroxylamine hydrochloride (942 mg, 5.9 mmol) and triethylamine (657 mg, 6.5 mmol) were 
added, and the mixture was stirred at 28°C for 25 h under argon. The reaction was worked up in 
exactly the same way described in 58, and the resulting thick oil was chromatographed on silica gel 
column with AcOEt-n-hexane 2:3, as eluent, to afford the corresponding O-benzyl hydroxamate 73 
as a white foamy solid, which strongly binds the aforementioned solvents. Removal of the entrapped 
solvents as in 60 gave 73 as a white solid (1.54 g, 76%): 129-131°C. This compound appears in the 1H 
and 13C NMR spectra as a mixture of E/Z conformers. 1H NMR (400 MHz, CDCl3) δ 0.93 (d, 3H, J=6.0 
Hz, CH(CH3)CH3), 0.96 (d, 3H, J=6.3 Hz, CH(CH3)CH3), 1.13-1.37 (br s, 1H, 1-H), 1.38-2.03 (complex m, 
14H, 7, 8, 9, 10, 11, 12-H, CH2CH(CH3)2), 2.27 (~t, 1H, J=9.9, 12.0 Hz, 12-H), 3.60 (d, 1H, J=8.0 Hz, 2-H),  
4.09-4.39 (br s, 1H, CH2CONHOCH2Ph), 4.45-4.69 (br s, 1H, CH2CONHOCH2Ph), 4.87 (s, 2H, 
CONHOCH2Ph), 7.37 (s, 5H, aromatic H), 8.24-8.44 (br s, 0.34H, CONHOCH2Ph), 8.75-8.93 (s, 0.37H, 
CONHOCH2Ph); 
13C NMR (50 MHz, CDCl3) δ 21.2 (CH(CH3)CH3), 21.8 (8-C), 22.7 (11-C), 23.5 
(CH(CH3)CH3), 24.5 (CH(CH3)2), 29.4, 29.6 (9, 10-C), 33.6 (7-C), 38.8 (12-C), 39.8 (CH2CONHOCH2Ph), 
40.3 (CH2CH(CH3)2), 51.8 (2-C), 61.2 (6-C), 78.5, 79.6 (CONHOCH2Ph), 128.8, 129.4 (2, 3, 4, 5, 6-
aromatic C), 134.9 (1-aromatic C), 165.7, 170.8 (CONHOCH2Ph), 174.3, 177.6 (3, 5-C); CI
+ MS: m/z 
416.2 ([M+H]+, 5), 359.1 ([M+H-CH2CH(CH3)2]
+, 5), 265.1 ([M-CONHOCH2Ph]
+, 18), 264.1 (59), 91.0 
(100). 
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Compound 73 (1.62 g, 3.9 mmol) was subjected to catalytic hydrogenation (10% Pd-C, 194 mg), in 
abs EtOH (175 mL) following the procedure previously described.[9] The hydrogenation material was 
chromatographed on silica gel column with AcOEt-n-hexane 3:1, as eluent, to afford the title 
compound 7d as a white foamy solid, which strongly binds the aforementioned solvents. Removal of 
the entrapped solvent as in 1e gave 7d as an off-white crystalline solid (1.18 g, 93%): mp 152-155°C; 
1H NMR (400 MHz, DMSO-d6) δ 0.88 (d, 3H, J=6.4 Hz, CH(CH3)CH3), 0.92 (d, 3H, J=6.8 Hz, 
CH(CH3)CH3), 1.33-1.80 (complex m, 12H, 7, 8, 9, 10, 11, 12-H, CH2CH(CH3)2), 1.83-2.0 (m, 2H, 
CH(CH3)2, 7-H),  2.02-2.16 (m, 1H, 12-H), 2.59 (d, 1H, J=12.4 Hz, 1-H), 3.41-3.56 (m, 1H, 2-H), 4.06-
4.19 (q, AB, 1.5H, JAB=15.6 Hz, CH2CONHOH, E-isomer), 4.35-4.51 (q, AB, 0.4H, JAB=16.8 Hz, 
CH2CONHOH, Z-isomer), 8.84 (s, 0.7H, CONHOH, E-isomer), 9.25 (s, 0.2H, CONHOH, Z-isomer), 10.13 
(s, 0.2H, CONHOH, Z-isomer), 10.48(s, 0.7H, CONHOH, E-isomer); 13C NMR (75 MHz, DMSO-d6) δ 21.1 
(CH(CH3)CH3), 21.3 (8-C), 22.3 (11-C), 23.5 (CH(CH3)CH3), 24.0 (CH(CH3)2), 29.1, 29.3 (9, 10-C), 33.1 (7-
C), 37.7 (12-C), 39.4 (CH2CONHOH), 39.5 (CH2CH(CH3)2), 51.1 (2-C), 60.2, 60.3 (6-C), 164.1 (CONHOH, 
E-isomer), 169.5 (CONHOH, Z-isomer), 174.1, 177.4 (3, 5-C);       
   -21 (c, 0.2, CHCl3); HRMS (ESI): 
[M-H]- calcd for C16H27N3O4, 324.1923, found, 324.1911. The hydrochloride salt (7d·HCl) was 
prepared as described for 1d·HCl. Mp 211-213°C (dec). Anal. Calcd for C16H28ClN3O4: C, 53.10; H, 
7.80; N, 11.61; Found: C, 53.39; H, 7.65; N, 11.32. 
 
2.2 Biological evaluation  
2.2.1 Trypanocidal assays 
Bloodstream form T. brucei (strain 221) were cultured in modified Iscove’s medium, as outlined 
previously.[13] Assays were performed in 96-well microtitre plates and the compound concentrations 
which inhibited growth by 50% (IC50) and 90% (IC90) were determined. Parasites were first diluted to 
2.5 × 104 mL−1, compounds were added at range of concentrations, and the plates incubated at 37 °C. 
Resazurin was added after 48 h (12.5 g/ml), the plates incubated for a further 16 h, and then read in 
a Spectramax plate reader (excitation 555 nm/emission 585 nm). Results were analysed using 
GraphPad Prism. Each drug concentration was tested in triplicate. 
 
T. cruzi epimastogotes (strain CL Brener) were cultured as described.[14] Trypanocidal activity was 
determined in microtitre plates as outlined above, with the following modifications. Experiments 
were initiated by seeding the parasites at 2.5 × 105 mL−1, and after the addition of test compounds, 
cultured at 28 °C for 4 days. Resazurin was added, the plates were incubated for a further 2 days, and 
then assessed as above.  
 
2.2.2 Leishmanicidal assays and cytotoxicity assays on murine macrophages J774.1. cells 
L. donovani (strain LG13, MHOM/ET/0000/HUSSEN), L. infantum (MHOM/GR/2002/GH12) and L. 
amazonensis (MPRO/BR/72/M1845) promastigotes  were cultured at 26 oC in RPMI 1640 (RPMI) 
medium supplemented with 10% heat-inactivated fetal bovine serum (fully supplmented RPMI), 10 
mM HEPES and antibiotics (penicillin/ streptomycin) as previously described.[15] The murine 
macrophage J774.1 cell line (American Type Culture Collection, Manassas, VA) was cultured as well as 
described above, in fully supplemented RPMI,  and incubated at 37 oC in 5% CO2. The inhibitory 
activity and the cytotoxicity of the compounds were determined with the use of an MTT-based assay, 
the Alamar blue, as previously described.[16] More specifically, 2.5X106 parasites/ml and 2X105 
macrophages/ml were seeded into 96-well plates (in total volume 200μl) and they were incubated 
for 72 hours with different concentrations of the compounds at 26 oC and 37 oC (in 5% CO2) 
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respectively.  20μl of alamar blue were added upon the 72 hour incubation and 24 hours later the 
colorimetric readings were performed (wavelength: 550 nm,  reference wavelength: 620 nm). The 
50% maximal inhibitory concentration (IC50) was calculated using a nonlinear regression curve fit.
[17]  
For evaluating the inhibitory activity of compounds against intracellular amastigotes, J774.1 
macrophages were seeded into 96-well flat bottom plates at a density of 2 × 105 cells/mL and a total 
volume of 200μl, and were left to adhere overnight at 37 °C in 5% CO2. Then, the macrophages were 
infected with stationary phase 4X106  promastigotes/ml, at a ratio of 10 parasites per 1 macrophage,  
and incubated for a further 24 h at 37 °C in 5% CO2 as previously described.
[16] Upon the incubation, 
the medium was removed, wells were thoroughly washed with PBS to remove free parasites and 
200μl of fresh medium containing the different concentrations of the compounds was added. The 
plate was incubated for further 72 hours at 37 °C in 5% CO2 and 20μl of alamar blue was added as 
described above. All experiments were performed at least three independent times in triplicate. 
 
2.2.3 Cytotoxicity assays on rat skeletal myoblast L6 cells 
Cytotoxicity against L6 cells was assessed using microtitre plates. Briefly, cells  were seeded in 
triplicate at 1 × 104 mL−1 in growth medium containing different compound concentrations. The 
plates were incubated for 6 days at 37 °C and resazurin then added to each well. After a further 8 h 
incubation, the fluorescence was determined using a Spectramax plate reader. 
 
3 RESULTS AND DISCUSSION 
3.1 Chemistry 
The synthetic routes for the preparation of the target compounds (1a-g, 2-5, 6a-d, 6f, 7a, 7b and 7d) 
is illustrated in Scheme 1. 2,6-Diketopiperazine-1-acetic acids 45-57 and 83-85 were the pivotal 
intermediates in preparing the acetohydroxamic acid analogues 1a-g, 2, 4, 5, 6a-d, 6f, 7a, 7b and 7d. 
Thus, coupling of these carboxylic acids with O-benzylhydroxylamine or O-benzyl-N-
methylhydroxylamine in the presence of 1,1’-carbonyldiimidazol (CDI) in THF or THF-DMF mixtures 
afforded the corresponding O-benzyl hydroxamates 58-64, 66-73 and 86-88 in yields 58-95%. 
Subsequent benzyl deprotection by hydrogenation over 10% Pd-C gave the respective hydroxamic 
acids 1a-g, 2, 4, 5, 6a-d, 6f, 7a, 7b and 7d. It is of note that this reductive deprotection provided 1a-
d, 1f, 1g, 2, 4, 5, 6a-d, 6f, 7a, 7b and 7d in high yields (80-96%), whilst it was low yielding (<10%) for 
1e. This is presumably due to catalyst poisoning by the methionine sulfide group. A better yield of 1e 
(25%) was achieved when the catalyst amount was 1.5-fold the weight of its corresponding O-benzyl 
hydroxamate precursor 61.  
 
The preparation of the chloro substituted hydroxamic acid 3 needed an alternative synthetic process 
as shown in Scheme 1. 4-Methoxybenzyl ester 38 was treated with trifluoroacetic acid (TFA) to give 
the respective carboxylic acid (not shown), which was coupled with O-(4-
methoxybenzyl)hydroxylamine in the presence of CDI to form the O-(4-methoxybenzyl) hydroxamate 
65 (70% from 38). Removal of the 4-methoxybenzyl protecting group of 65 was effected by 
treatment with trifluoroacetic acid in the presence of triethylsilane to give the  desired compound 3 
in 89% yield. The requisite 4-methoxybenzyl ester 38 was synthesized from 24 as described for the 
preparation of the benzyl esters 31-37 and 39-44, except that 4-methoxybenzyl bromoacetate was 
used in place of benzyl bromoacetate. It is noteworthy that the 4-methoxybenzyl bromoacetate[18, 19] 
used was prepared by employing a new facile and efficient experimental protocol involving the 
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treatment of 4-methoxybenzyl alcohol with bromoacetyl chloride in the presence of NaHCO3 in dry 
CH2Cl2 (Supporting Information).  
 
The 1H and 13C NMR spectra for all acetohydroxamic acid analogues (compounds 1a-g, 2-5, 6a-d, 6f, 
7a, 7b and 7d) are consistent with a Z/E conformational behavior of these molecules in solution. The 
NMR spectral data of compounds 1a-c, 1f, 1g, 2, 6a-c, 6f, 7a and 7b have already been reported.[9] 
However, the assignment of the Z and E conformers given in this report was erroneous. Our next, 
more detailed conformational study,[10] has reversed these assignments, i.e. the original data 
referring to the E isomer correspond to the Z isomer structure and vice versa.  
 
3.2 Biological evaluation 
Compounds 1a-g, 2-5, 6a-d, 6f, 7a, 7b and 7d were tested against bloodstream form T. brucei in 
vitro. Analogues 1a, 1b and 1f were also tested against T. cruzi epimastigotes. The results are shown 
in Table 1 and expressed as IC50 and IC90 values. The in vitro anti-leishmanial activity of compounds 
1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d was evaluated against promastigote and intracellular amastigote 
forms of L. infantum GH12, L. donovani LG13 and L. amazonensis LV78. The IC50 values are given in 
Table 2. The cytotoxicities of the hydroxamic acid derivatives against mammalian cells were 
determined using the rat skeletal myoblast L6 and murine macrophage J 174.1 cell lines. 
 
Inspection of Table 1 shows that compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d exhibited potent 
activity against T. brucei as either free bases or hydrochloride salts (IC50 = 6.6-1870 nM and 9.2-1150 
nM respectively). In particular, compounds 1f, 1g, 2, 3, 6d and 6f were the most potent against 
African trypanosomes, with IC50 values in the low nanomolar range (6.8-72 nM), while hydroxamates 
1a, 1b and 1f were found to be significantly active against T. cruzi epimastigotes. Structure-activity 
relationship studies show that the substitution pattern of the spiro carbocyclic 2,6-DKP scaffold is an 
essential factor in the trypanocidal potency of these acetohydroxamic acid-based analogues.  
 
Methylation on the basic nitrogen of the 2,6-DKP ring of the adamantane parent compound 1a 
resulted in 2.1-fold less activity against T. brucei (compare 7b vs 7a). However, analogous 
methylation on the cyclooctane and cycloheptane parent molecules 6a and 7a provided a 1.9 and 
6.6-fold increase in the potency of their N-methyl analogues 6b and 7b, respectively (Table 1). These 
results indicate that N-methyl substitution on the 2,6-DKP ring has a favorable effect on the 
trypanocidal activity only in the cases of the cyclooctane or cycloheptane-containing 
acetohydroxamic acid analogues in this series of compounds. 
 
Table 1. 
 
We next investigated the effect of alkyl or arylmethyl substitution at the vicinal position of the basic 
nitrogen atom within the spiro carbocyclic 2,6-DKP framework,  using methyl, isobutyl, 2-
(methylthio)ethyl, benzyl and 4-chlorobenzyl substituents. As shown in Table 1, introduction of a 
methyl, isobutyl or 2-(methylthio)ethyl substituent to the adamantane parent 1a, leading to the (S)-
enantiomer of the corresponding C-alkylated analogues 1c, 1d and 1e, reduced potency against  T. 
brucei. Compounds 1c, 1d and 1e, in the free base form, were 1.5, 3.1 and 1.9-fold less potent than 
1a. The lowest activity relative to 1a resulted from the introduction of an isobutyl group (1d). 
However, similar C-methylation or isobutylation of the cyclooctane parent molecule 6a appeared to 
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have a beneficial effect on the trypanocidal potency; the resulting (S)-methyl and (S)-isobutyl 
substituted analogues 6c and 6d had 2.4 and 4.2-fold better activities than 6a, respectively. It is 
interesting that a significantly improved activity (19-fold) was observed with the cycloheptane-
containing (S)-isobutyl substituted congener 7d relative to the parent compound 7a. Therefore, the 
presence of a methyl or isobutyl group at the vicinal position of the amine nitrogen atom in the 2,6-
DKP ring seems to favor trypanocidal potency toward T. brucei in the context of the spiro 
cyclooctane or cycloheptane 2,6-diketopiperazine-1-acetohydroxamic acids. 
 
Attachment of a bulky hydrophobic substituent, such as a benzyl or 4-chlorobenzyl group, to the 
methylene carbon in the 2,6-DKP ring of the parent molecules 1a and 6a led to the most potent 
analogues (1f, 1g, 2, 3 and 6f) in this series against bloodstream-form T. brucei, with activity in low 
nanomolar range (IC50 = 6.8-32 nM, Table 1). Of the adamantane-based compounds possessing a 
benzyl substituent, the S-enantiomer (1f, IC50 = 6.8 nM) was more potent than the R-enantiomer 
counterpart (1g, IC50 = 9.1 nM), or racemate (2, IC50 = 17 nM). Their activities in the free base form 
were found to be 5.3-13 times higher than the unsubstituted parent 1a and 8-42 times higher than 
their C-menthyl and C-isobutyl substituted congeners 1c and 1d. Incorporation of a 4-chlorobenzyl 
substituent at the same position of the parent 1a, leading to the racemate p-chlorobenzyl 
substituted derivative 3, caused an increase in activity (2.8-fold), albeit to a lesser extent than the 
respective benzylic substitution (racemate 2 vs 3). A similar potency profile was observed for the 
cyclooctane C-benzyl substituted analogue 6f (S-enantiomer). This compound was significantly more 
potent (10-fold) than the parent 6a, and had 4.3 and 2.5 more trypanocidal activity than the (S)-
enantiomers of the C-methyl and C-isobutyl counterparts 6c and 6d, respectively (Table 1). The 
higher increase in potency of the C-benzylated analogues 1f, 1g, 2, 3 and 6f is ascribed to the 
strongly favorable stereoelectronic and lipophilic effects exerted by the benzylic substituent in the 
binding site.   
The adamantane-containing free bases 1a, 1b and 1f were significantly active against cultured T. 
cruzi epimastigotes, with micromolar to submicromolar IC50 values (Table 1). It is noteworthy, that N-
methylation in analogue 1b leads to an opposite effect to that in T. brucei. Similarly, C-benzylation 
on 1a, giving compound 1f, led to a much more potency against T. cruzi (26-fold).[9] 
 
The results of the in vitro assay for the anti-leishmanial activity of compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 
7b and 7d are presented in Table 2. These compounds were first screened against the promastigote 
form of each of the three Leishmania sp. at 10 μM. IC50 values were further determined for those 
displaying 100% parasite growth inhibition at this concentration. 
 
The unsubstituted parent compounds 1a, 6a, 7a and their substituted derivatives 1b, 1c, 1e, 6b, 6c, 
6f and 7b had a marginal activity toward all the Leishmania sp. tested. In contrast, compounds 
bearing an isobutyl substituent at the vicinal position of the nitrogen atom of the respective spiro 
carbocyclic 2,6-DPK residue (1d, 6d, 7d), or compounds possessing a benzylic or 4-chlorobenzylic 
substituent at the same position of the adamantane-based spiro 2,6-DPK core (1f, 1g, 2, 3), exhibited 
significant activities against L. infantum promastigotes and intracellular amastigotes, in either free 
base form or hydrochloride salt, with IC50 values at micromolar to low micromolar levels. Their anti-
promastigote and anti-amastigote activities in the free base form were in the range of 2.67-17.7 μM 
and 2.23-7.85 μM, respectively. Similar ranges of activities against the two forms of this parasite 
were detected for the corresponding hydrochloride salts (2.86-13.2 μM and 2.04-8.90 μM, 
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respectively). Moreover, compounds 1g and 2 exhibited micromolar or low micromolar activities 
against L. donovani (Table 2). None of the tested compounds showed any significant activity against 
L. amazonensis promastigotes. 
 
Relative to the parent structures 1a, 6a and 7a, the C-isobutyl analogues 1d, 6d and 7d, (S-
enantiomers) were active against the L. infantum promastigotes (1d, IC50= 7.23 μM, 6d, IC50= 6.16 
μM, and 7d, IC50= 17.7 μM). However, they gave better potencies (3.2, 1.8 and 2.3-fold, respectively) 
toward the intracellular amastigotes, indicating that this form of L. infantum is more sensitive to 
these compounds. In both cases, the cycloheptane-containing C-isobutyl analogue 7d was less 
potent than the adamantane and cyclooctane congeners 1d and 6d, respectively (Table 2). No 
significant activity against the two other Leishmania sp. was observed with the isobutyl analogues 
1d, 6d and 7d. As it is evident from Table 2, the adamantane-based C-benzyl or 4-chlorobenzyl 
substituted analogues 1f, 1g, 2 and 3 were the most efficient growth inhibitors of both forms of L. 
infantum, possessing activities in the low micromolar range (promastigotes form, IC50=2.67-4.85 μΜ, 
and amastigote form, IC50=2.43-4.40 μΜ). These analogues in the free base form were 1.5-2.7-fold 
more effective than the isobutyl counterpart 1d against promastigotes, while their efficacy toward 
intracellular amastigotes was comparable to that of 1d. Among the C-benzylated compounds (1f, 1g, 
2), the S-enantiomer 1f was the most potent and selective against L. infantum exhibiting almost 
equal anti-promastigote and anti-amastigote potencies. It was 1.4 and 1.7-fold more active than the 
corresponding R-enantiomer 1g against promastigotes and intracellular amastigotes, respectively. A 
similar result against the promastigote form of L. infantum was observed when comparing 1f to the 
racemic compound 2. Somewhat surprisingly, the S-enantiomer 1f was almost equipotent to the 
racemic mixture 2 (1f, IC50=2.60±1.37 μΜ; 2, IC50=2.74±1.59 μΜ) toward intracellular amastigotes, 
when these compounds were tested as free bases. However, a difference in activity was detected 
between their respective hydrochlorides, with 1f.HCl (S-enantiomer) being more potent (2.3-fold) 
than 2.HCl (racemic), as expected. Noticeably, enhanced activities were observed against 
promastigotes of L. donovani in the cases of the R-enantiomer 1g and racemate 2, when compared 
to the corresponding S-enantiomer 1f. They retained low micromolar anti-promastigote potencies, 
although the racemic mixture 2 was slightly less active. R-enantiomer 1g also exhibited a noteworthy 
activity toward the intracellular amastigotes in the free base form (IC50= 15.0 μM). These findings 
indicate that the R-stereochemistry is preferred over the S with respect to L. donovani potency. 
Introduction of a chlorine atom at the benzene ring 4-position of the benzylic substituent in the 
racemic compound 2 slightly reduced the potency against L. infantum promastigotes, as shown from 
the IC50 values of compounds 2 and 3 (Table 2). On the other hand, this chloro-substitution did not 
significantly affect the activity against the intracellular amastigotes, when the analogues 2 and 3 
were screened as free bases, while a marked difference in potency was detected between the 
corresponding hydrochloride salts (2.HCl and 3.HCl). In the case of the latter, the hydrochloride salt 
of the chloro-substituted compound 3 was 3.9 times more potent than the hydrochloride salt of its 
unsubstituted counterpart 2.   
 
On the basis of these anti-leishmanial data, the presence of a branched alkyl chain, such as isobutyl 
group, at the vicinal position of the nitrogen atom of the 2,6-DKP ring of compounds 1d, 6d and 7d, 
or a benzyl substituent at the same position of the adamantane-based compounds 1f, 1g, 2 and 3, is 
responsible for their enhanced potency. This points to the important influence of these substituents 
in determining anti-leishmanial activity, possibly due to lipophilic and/or stereoelectronic effects. 
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The observed differences in activity (anti-trypanosomal or anti-leishmanial) between the free base 
and the corresponding hydrochloride salt forms (Table 1 and 2) might be due to their differential cell 
permeability, resulting from differences in solubility at the pH of the culture media.  
 
It is noteworthy that the active compounds, show very low cytotoxicity against mammalian cells (rat 
skeletal myoblast L6 and murine macrophage J 774.1 cell lines). In the case of the myoblast L6 cells, 
the selectivity indices varied from 63 (1e) to more >3600 (1a). With respect to the murine 
macrophage cells, the IC50 values were found to be >200 μΜ, with the exception of compound 1f 
(IC50=29.2 μΜ). These results indicate significant selectivity of the compounds, up to two orders of 
magnitude greater than has been reported previously for DKP-based compounds with activity 
against T. brucei.[20] If similar properties can be established in vivo, this would represent a significant 
advantage over current trypanocidal drugs, where toxic side effects are one of the major drawbacks. 
In this study, despite the lower antileishmanial activity of antimonials- and thus similar activity to the 
most active hydroxamic acid derivatives,  in comparison to amphotericin B[15,21] (i.e. 135 times lower 
for Glucantime over amphotericin B[21]), we selected not to use antimonials as reference drugs, as 
parasites may have inherent or even develop spontaneous drug resistance during in vivo or cell-
culture passages. We thus validated the phenotypic screen by using the highly active amphotericin B. 
Our results show that the inhibitory activity of Amphotericin B (IC50  = 0.09 μΜ and 0.10 μΜ in L. 
infantum and L. donovani promastigotes respectively and 0.18 μΜ and 0.20 μΜ L. infantum and L. 
donovani in intracellular amastigotes respectively) is in the anticipated range.[22]  
 
4 CONCLUSION  
The present work has extended the structure-activity relationships of spiro carbocyclic 2,6-DKP-1-
acetohydroxamic acids in determining in vitro growth inhibition of trypanosomal and leishmanial 
parasites. Our studies demonstrate that the anti-parasitic activity of this class of compounds is 
greatly dependent upon the alkyl or the arylalkyl substitution on either the basic nitrogen atom (N-
methylation) or at its vicinal position (C-alkylation or arylmethylation) in the spiro carbocyclic 2,6-
DKP skeleton. N-methylation had a positive influence on the potency against blood-stream form T. 
brucei, only in the cases of cyclooctane or cycloheptane-containing analogues (Table 1, compounds 
6b, 7b). C-methylation or isobutylation (C-alkylation) reduced potency for the adamantane-based 
(S)-methyl and (S)-isobutyl substituted analogues 1c and 1d, respectively. In contrast, enhanced 
activity against T. brucei was observed for the cyclooctane and cycloheptane (S)-methyl or (S)-
isobutyl counterparts (6c, 6d, 7d), although the isobutylation produced a more pronounced effect 
with respect to the methylation. In contrast, C-arylmethylation, such as C-benzylation or 4-
chlorobenzylation, yielded (S) or (R)-chiral or racemic analogues (1f, 1g, 2, 3), which were the most 
potent against bloodstream-form T. brucei, with low nanomolar IC50 values (6.8-32 nM) as shown in 
Table1. Of note, compounds 1a, 1b and 1f displayed significant activity against T. cruzi 
epimastigotes. The (S)-chiral benzyl substituted compound 1f was the most active derivative against 
T. brucei and T. cruzi, with IC50 values of 6.8 nM and 210 nM, respectively. In the case of T. cruzi, this 
value is 5-10 fold lower than the current front line drugs, benznidazole and nifutimox.[23]  
With respect to the anti-leishmanial activity of the tested compounds, only the C-isobutylation or C-
arylmethylation (C-benzylation or 4-chlorobenzyaltion) produced a significant anti-parasitic toxicity 
against the L. infantum promastigotes and amastigotes (Table 2, compounds 1d, 1f, 1g, 2, 3, 6d). 
However, this was not the case for the cyclooctane C-benzylated analogue 6f. Among the C-
benzylated compounds 1f, 1g and 2, the S-enantiomer 1f was the most potent and selective against 
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L. infantum. However, the R-enantiomer 1g and the racemate 2 displayed satisfactory micromolar 
activities against L. donovani, as compared to the corresponding S-enantiomer. These results are 
indicative of the enhanced potency of the R-enantiomer against L. donovani. The addition of a 
chlorine atom at the benzene ring C4-position of the benzylic substituent in the racemic compound 2 
has a little effect on the potency toward L. infantum (Table 2, 3 vs 2).  
In summary,  the data obtained from this study show that introduction of branched alkyl (e.g. 
isobutyl) or benzylic substituents at the vicinal position of the amine nitrogen of the 2,6-DKP 
skeleton tends, in general, to generate analogues with greatly enhanced activity toward 
trypanosomal and leishmanial parasites. We surmise that this could be due to the strong lipophilic 
and/or stereoelectronic influence of these bulky substituents in the target binding site. Importantly, 
the most potent compounds were found not to have significant toxicity against mammalian cells, 
indicating a high selectivity over the parasites. The results suggest that these acetohydroxamic acid 
derivatives can be considered promising structures for further investigation in developing new more 
efficient and safe agents for the treatment of trypanosomiasis or leishmaniasis. Efforts in this 
direction, including modifications on either the spirocarbocyclic 2,6-DKP residue or the 
acetohydroxamate acid pharmacophoric moiety, while retaining the carbohydroxamic acid unit 
(CONHOH), are currently underway.  
 
 
Figure and Scheme legends 
 
Figure 1. Structures of lipophilic spiro carbocyclic 2,6-diketopiperazine-1-acetohydroxamic acid derivatives 1a-g, 2-5, 6a-d, 
6f, 7a, 7b and 7d. 
 
Scheme 1. Reagents and conditions: (a) NaCN, appropriate α-amino acid alkyl ester hydrochloride, DMSO/H2O 
29:1 (v/v), rt, 48 h; (b) (i) H2SO4 97% for 17, 18, 25, rt, 24h or H2SO4 97%, CH2Cl2, rt, 24 h for 19, 20, 26-30 or 48 
h for 21-24; (ii) ice and then aq NH3 26% to pH 7-8; (c) (i) (Me3Si)2NK (1 equiv), THF, 0-5°C, then rt, 1 h, argon; 
(ii) BrCH2CO2CH2Ph or BrCH2CO2CH2C6H4OCH3-4 only for 38, DMF, rt, 48 h, argon, 78-95% for 31-37, 38-42, 44, 
62% for 43 from 8; (d) H2/Pd-C 10%, EtOH for 45, 46, 52, 53, 56, 83-85, 1a-d, 1f, 1g, 2, 4, 5, 6a-d, 6f, 7a, 7b, 7d 
or EtOH-AcOEt 3:2 (v/v) for 47-51, 54, 55, 57, 1e, 50 psi, rt, 3 h, >99% for 45-47, 49-57, 83-85, 86% for 48, 80-
96% for 1a-d, 1f, 1g, 2, 4, 5, 6a-d, 6f, 7a, 7b, 7d, 25% for 1e; (e) (i) CDI, THF for 58-64, 66, 67, 69, 71, 86-88 or 
THF/DMF 3:4 for 68 or THF/DMF 6:1 for 70, 73 or THF/DMF 4:1 for 72, 28°C, 1 h, argon; (ii) PhCH2ONH2 · HCl, 
Et3N or PhCH2ONHCH3 for  66, 67, 28°C, 25 h, argon, for 59-63, 69-71, 73 or 28°C, 24 h, then 45°C, 1 h, argon 
for 58, 64, 66-68, 72, 86-88, 58-95% for 58-60, 62-64, 66-73, 86-88, 62% for 61 from 34 (f) (i) CF3CO2H, CH2Cl2, 
rt, 90 min; (ii) CDI, Et3N, THF, 28°C, 1 h; (iii) 4-CH3OC6H4CH2ONH2, 28°C, 24 h, then 55°C, 1 h, 70% from 38; (g) 
CF3CO2H, CH2Cl2, rt, 10 min, then Et3SiH, rt, 45 min, 89% from 65; (h) as (c) (i), then CF3CO2H (1 equiv), >99%; (i) 
(i) aq CH2O 37%, MeOH/THF 1:1 for 77 or MeOH/THF 1:3 for 78, 79, rt, 3 h, then NaCNBH3, rt, 4 h, at pH 6-7 
(maintained by adding AcOH); (ii) 1N NaOH and Na2CO3 to pH 8, 80-92%; (j) NaH, DMF, rt, 1 h, argon and then 
as (c) (ii) using BrCH2CO2CH2Ph, 83-92%. 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
REFERENCES 
[1] http://www.who.int/mediacentre/factsheets/fs259/en/. Trypanosomiasis, human African 
(sleeping sickness) (2017).  
[2] K. Hashimoto, and K. Yoshioka. Review: surveillance of Chagas disease. Adv. Parasitol. 79 
(2012), 375. 
[3] http://www.who.int/mediacentre/factsheets/fs375/en/. Leishmaniasis (2016). 
[4] S. L. Croft, S. Sundar, A. H. Fairlamb, Clin. Microbiol. Rev. 2006, 19, 111. 
[5] A. S. Nagle, S. Khare, A. B. Kumar, F. Supek, A. Buchynskyy, C. J. N. Mathison, N. K. 
Chennamaneni, N. Pendem, F. S. Buckner, M. H. Gelb, V. Molteni, Chem. Rev. 2014, 114, 
11305. 
[6] J. Pépin, F. Milord, A. N. Khonde, T. Niyonsenga, L. Loko, B. Mpia, P. De Wals, Trans. R. Soc. 
Trop. Med. Hyg. 1995, 89, 92. 
[7] J. Robays, G. Nyamowala, C. Sese, V. Betu Ku Mesu Kande, P. Lutumba, W. Van der Veken, 
M. Boelaert, Emerg. Infect. Dis. 2008, 14, 966. 
[8] C. Burri, R. Brun, Parasitol. Res. 2003, 90 (Supp 1), S49. 
[9] C. Fytas, G. Zoidis, N. Tzoutzas, M.C. Taylor, G. Fytas, J. M. Kelly, J. Med. Chem. 2011, 54, 
5250. 
[10] A. Tsatsaroni, G. Zoidis, P. Zoumpoulakis, A. Tsotinis, M. C. Taylor, J. M. Kelly, G. Fytas, Tet. 
Lett. 2013, 54, 3238. 
[11] G. Malik, X. Guinchard, D. Crich, Org. Lett. 2012, 14, 596. 
[12]  C. Fytas, G. Zoidis, G. Fytas, Tetrahedron 2008, 64, 6749. 
[13] M. C. Taylor, M. D. Lewis, A. Fortes Francisco, S. R. Wilkinson, J. M. Kelly, PLoS Negl. Trop. 
Dis. 2015, 9, e0003707. 
[14] G. Kendall, A. F. Wilderspin, F. Ashall, M. A. Miles, J. M. Kelly, EMBO J. 1990, 9, 2751. 
[15] A. Alexandratos, J. Clos, M. Samiotaki, A. Efstathiou, G. Panayotou, K. Soteriadou, D. Smirlis, 
Mol. Microbiol. 2013, 88, 1015.   
[16] A. Efstathiou, N. Gaboriaud-Kolar, D. Smirlis, V. Myrianthopoulos, K. Vougogiannopoulou, A. 
Alexandratos, M. Kritsanida, E. Mikros, K. Soteriadou, A.-L. Skaltsounis, Parasit Vector. 2014, 
7, 1.  
[17]  J. F. Oliveiro Costa, A. C. Kiperstok, J. Pereira de Lima David, J. M. David, A. M. Giulietti, L. 
Paganucci de Queiroz, R. R. dos Santos, M. B. P. Soares, Fitoterapia 2007, 78, 510. 
[18] M. Shibata, T. Kashiwamura, A. Yomogita, H. Ishii, M. Sekikawa, H. Shiotani, T. Owada, PCT 
Int. Appl., 2010067627, 17 Jun 2010. 
[19] K. H. Boltze, H. Horstmann, Ger. Offen., 3206885, 15 Sep 1983. 
[20] K. R. Watts, J. Ratnam, K. H. Ang, K. Tenney, J. E. Compton, J. McKerrow, P. Crews, Bioorg. 
Med. Chem. 2010, 18, 2566. 
[21] D. C. Ayres, L. A. Pinto, S. Giorgio, J. Parasitol. 2008, 94, 1415. 
[22] M. García, R. Scull, P. Satyal, W. N. Setzer, L. Monzote, Phytother. Res. 2017, doi: 
10.1002/ptr.5869. 
[23] S. R. Wilkinson, C. Bot, J. M. Kelly, B. S. Hall, Curr. Topics Med.Chem. 2011, 16, 2072.  
  
SUPPORTING INFORMATION 
Additional Supporting Information may be found online in the supporting information tab for this 
article.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Table 1. Activity of acetohydroxamic acid analogues 1a-g, 2-5, 6a-d, 6f, 7a, 7b and 7d (Figure 1) tested against cultured bloodstream-form 
T. brucei (pH=7.4) and T. cruzi epimastigotes, and cytotoxicity of the most active compounds against cultured rat skeletal myoblast L6 cells 
(Supporting information). 
 
Cpds 
Activity Cytotoxicity 
T. brucei T. cruzi L6 cells 
IC50 (nM)
a,b,c
 IC90 (nM)
a,b,c
 IC50 (nM)
a,b
 IC90 (nM)
a,b
 IC50 (nM)
d
 SI
e
 
1a 90±16 (79±6)
c
 155±7 (148±8)
c
 5510±680 11110±1190 >325000 >3600 
1b 193±28 (340±28) 328±28 (622±84) 3620±310 5990±160 40400±5600 210 
1c 134±33 (405±98) 276±12 (909±209) - - - - 
1d 283±27 (253±35) 462±99 (355±17) - - 32000±2000 110 
1e 168±42 (163±11) 251±14 (248±6) - - 10500±500 63 
1f 6.8±1.4 (42±5) 11.5±2 (80±22) 210±40 360±10 10400±900 1500 
1g 9.1±0.2 (9.2±0.5) 14±1 (14±1) - - 11600±1500 1300 
2 17±1 (18±1) 26±3 (24±1) - - 23700±400 1400 
3 32±4 (31±3) 43±3 (40±2) - - 21000±1000 660 
4 246×10
3 
(106×10
3
) 523×10
3 
(198×10
3
) - - - - 
5 37×10
3 
(35×10
3
) 47×10
3 
(45×10
3
) - - - - 
6a 300±25 (266±19) 635±14 (495±28) - - - - 
6b 158±34 (162±15) 300±34 (327±9) - - - - 
6c 125±30 (134±13) 270±41 (259±25) - - - - 
6d 72±2 (73±3) 92±9 (111±4) - - 204000±47000 2830 
6f 29±3 (25±2) 39±1 (35±1) - - 93800±18800 3200 
7a 1870±80 (1150±130) 2530±290 
(1710±40) 
- - - - 
7b 285±9 (311±7) 673±56 (717±113) - - - - 
7d 99±4 (97±9) 148±8 (135±15) - - 191000±2000 1930 
aConcentrations required to inhibit growth of T. brucei and T. cruzi by 50% and 90%, respectively. 
bFor the active compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d, IC50 and IC90 data are the mean of triplicate experiments ± SEM. 
cIC50 and IC90 for the respective hydrochloride are shown in brackets. 
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dCytotoxicity was determined by establishing the concentration required to inhibit growth of cultured L6 cells by 50% (IC50) (Supporting 
Information). Data are the mean of triplicate experiments ± SEM. eSelectivity indices were calculated as the ratio of the IC50 for L6 cells and 
IC50 for T. brucei. 
 
 
 
Table 2. In vitro inhibitory activity of acetohydroxamic acid analogues 1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d (Figure 1) against Leishmania sp. 
promastigotes and intracellular amastigotes, and their cytotoxicity against murine macrophages J 774.1.    
 
 
Cpds 
L. infantum GH12 
IC50 (μM)
a,b,c 
L. donovani Lg13 
IC50 (μM)
a,b,c 
Macrophages 
J774.1. 
IC50 (μM)
d 
       
promastigotes 
      
intracellular 
amastigotes 
  promastigotes    intracellular 
amastigotes 
1a            ni
 
         -           ni          - >200 
1b  ni          - ni - >200 
1c  ni          -  ni - >200 
1d 7.23±0.25 
(7.32±1.78)
c
 
 2.23±1.26 
(2.76±1.11) 
  -          >200 
1e ni -  ni - >200 
1f  2.67±0.70 
(2.86±0.98) 
 2.60±1.37 
(3.51±1.20) 
 ni - 29.3 (32) 
1g  3.70±0.23 
(2.95±0.86) 
 4.40±0.69 
(4.70±0.43) 
  8.35±0.86 
(6.51±0.32) 
 15±1.57 
(18±1.34) 
>200 
2   3.80±0.46 
(4.05±0.28) 
 2.74±1.59 
(7.90±0.78) 
  9.73±0.33 (ni)                     - >200 
3   4.85±1.22 
(4.26±1.39) 
2.43±1.18 
(2.04±0.77) 
ni          - >200 
6a  ni - ni - >200 
6b  ni - ni  - >200 
6c ni - ni  - >200 
6d  6.16±1.29 
(5.96±0.73) 
 3.50±1.44 
(3.20±1.59) 
ni  - >200 
6f ni - ni  - >200 
7a  ni - ni  - >200 
7b  ni  - ni  - >200 
7d  17.7±1.96 
(13.2±0.35) 
 7.85±1.56 
(8.90±0.46) 
ni  - >200 
Amphotericin B 0.09 ± 0.005  0.18 ± 0.02 0.10 ± 0.01  0.20 ± 0.02 - 
 aConcentrations required to inhibit growth of Leishmania sp promastigotes and intracellular amastigotes by 50%. bIC50 data are the means 
of triplicate experiments ± SEM. cIC50 data for the respective hydrochloride are shown in brackets. 
dCytotoxicity  against the murine 
macrophage cell-line J 774.1. eni - no inhibition at 10 μM. 
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